Results 41 to 50 of about 15,900 (130)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

Journal of Hematology & Oncology, 2021
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL).
Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin, Geoffrey Chong, Wojciech Jurczak, Ka Lung Wu, Mark Bishton, Graham P. Collins, Paul Eliadis, Frédéric Peyrade, Yihua Lee, Karl Eckert, Jutta K. Neuenburg, Constantine S. Tam   +14 more
doaj   +1 more source

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study

Cancer Medicine, 2018
In the Asia‐Pacific region, treatment options are limited for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Xiaojun Huang, Lugui Qiu, Jie Jin, Daobin Zhou, Xiequn Chen, Ming Hou, Jianda Hu, Yu Hu, Xiaoyan Ke, Junmin Li, Yingmin Liang, Ting Liu, Yue Lv, Hanyun Ren, Aining Sun, Jianmin Wang, Chunting Zhao, Mariya Salman, Steven Sun, Angela Howes, Jingzhao Wang, Peng Wu, Jianyong Li   +22 more
doaj   +1 more source

GPR83 protects cochlear hair cells against ibrutinib-induced hearing loss through AKT signaling pathways

Frontiers in Medicine
IntroductionIbrutinib, widely used in leukemia treatment, has been implicated in sensorineural hearing loss; however, its underlying mechanisms remain unclear.MethodsThis study investigated the impact of ibrutinib on hearing using HEI-OC1 cells, cochlear
Yuhua Zhang, Yun Xiao, Yongjun Zhu, Lin Yan, Nan Cheng, Yongjie Wei, Yanling Zhang, Yanghua Tian, Wei Cao, Jianming Yang   +9 more
doaj   +1 more source

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Experimental Hematology & Oncology, 2019
Background The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models.
Alexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman, Sara Ek   +3 more
doaj   +1 more source

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia

Molecular Medicine, 2019
Background Streptococcus pneumoniae is a major causative agent in community-acquired pneumonia and sepsis. Overwhelming lung inflammation during pneumococcal pneumonia may hamper lung function.
Alexander P. de Porto, Zhe Liu, Regina de Beer, Sandrine Florquin, Onno J. de Boer, Rudi W. Hendriks, Tom van der Poll, Alex F. de Vos   +7 more
doaj   +1 more source

Ibrutinib [PDF]

Australian Prescriber, 2015
  +5 more sources

Mitigating Ibrutinib‐Induced Ventricular Arrhythmia and Cardiac Dysfunction With Metformin

Cancer Innovation
Background Ibrutinib is a first‐line drug that targets Bruton's tyrosine kinase for the treatment of B cell cancer. However, cardiotoxicity induced by ibrutinib is a major side effect that limits its clinical use.
Pengsha Li, Daiqi Liu, Pan Gao, Ming Yuan, Zhiqiang Zhao, Yue Zhang, Zandong Zhou, Qingling Zhang, Meng Yuan, Xing Liu, Gary Tse, Guangping Li, Qiankun Bao, Tong Liu   +13 more
doaj   +1 more source

Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis

Blood Neoplasia
: Hypertension is a common side effect of Bruton tyrosine kinase inhibitors (BTKis). The second-generation BTKi zanubrutinib has high BTK selectivity, which may minimize off-target effects.
June-Wha Rhee, Nicole Lamanna, Wassim Aldairy, Lipeng Chen, Jun Zhang, Dulce Ramirez, William B. White   +6 more
doaj   +1 more source

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Haematologica, 2018
Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy.
Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian Hill, Christina Howlett, Alan Skarbnik, Bruce D. Cheson, Clive Zent, Jeffrey Pu, Pavel Kiselev, Andre Goy, David Claxton, Krista Isaac, Kaitlin H. Kennard, Colleen Timlin, Daniel Landsburg, Allison Winter, Sunita D. Nasta, Spencer H. Bachow, Stephen J. Schuster, Colleen Dorsey, Jakub Svoboda, Paul Barr, Chaitra S. Ujjani   +25 more
doaj   +1 more source

Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Frontiers in Hematology
BackgroundMantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses ...
Catarina Fernandes, Rita Costa e Sousa, Pedro Santos, Cátia Almeida, Adriana Roque, Ana Luísa Pinto, Joaquim Monteiro, Anabela Neves, Maria João Ramos, Rita Coutinho, Rita Coutinho, Rita Coutinho, Filipa Mousinho, Mariana Leal Fernandes, Margarida Badior, Cristina João, Cristina João, Sónia Leocádio, Ana Luísa Tomé, Margarida Carrolo, Sara Dias, Maria Gomes da Silva, João Paulo Fernandes   +22 more
doaj   +1 more source